Pun Patrick H, Lehrich Ruediger W, Smith Stephen R, Middleton John P
Department of Medicine, Division of Nephrology, Duke University Medical Center, Durham, North Carolina, USA.
Clin J Am Soc Nephrol. 2007 May;2(3):491-500. doi: 10.2215/CJN.02360706. Epub 2007 Feb 14.
Cardiac arrest (CA) is the most common cause of death in hemodialysis patients, and factors that improve survival after arrest are unknown. This study sought to identify modifiable factors that are associated with survival after CA in hemodialysis clinics. Patients who experienced in-center CA in the Gambro Healthcare System in the United States from 2002 to 2005 were identified. Patient characteristics at the time of arrest were compared between survivors and nonsurvivors at 24 h and 6 mo after CA. A total of 729 patients sustained in-clinic CA; 310 (42.5%) patients survived 24 h, and 80 (11%) patients survived 6 mo. Traditional risk factors, including cardiovascular comorbidities, diabetes, hemoglobin, and dialysis adequacy, did not predict survival at either time point. After adjustment for case-mix factors, presence of indwelling catheter, and concomitant medications, only use of beta blockers (BBL), calcium-channel blockers (CCB), and angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) remained significantly associated with survival (BBL odds ratio [OR] 0.32 [95% confidence interval (CI) 0.17 to 0.61]; CCB OR 0.42 [95% CI 0.23 to 0.76]; ACEI/ARB OR 0.51 [95% CI 0.28 to 0.95]). The beneficial effect of ACEI/ARB and BBL on survival increased sequentially with higher medication dosages. Prescription of BBL at the time of the event was the only predictive variable of survival at 24 h. Therefore, traditional cardiovascular risk factors were not associated with survival after CA in this hemodialysis cohort. The benefits that are associated with BBL, CCB, and ACEI/ARB suggest that these medications may improve the chances of survival after CA.
心脏骤停(CA)是血液透析患者最常见的死亡原因,而心脏骤停后改善生存的因素尚不清楚。本研究旨在确定血液透析诊所中与心脏骤停后生存相关的可改变因素。对2002年至2005年在美国甘布罗医疗保健系统中经历院内心脏骤停的患者进行了识别。比较了心脏骤停幸存者和非幸存者在心脏骤停后24小时和6个月时的骤停时患者特征。共有729例患者发生院内心脏骤停;310例(42.5%)患者存活24小时,80例(11%)患者存活6个月。包括心血管合并症、糖尿病、血红蛋白和透析充分性在内的传统危险因素在两个时间点均不能预测生存情况。在对病例组合因素、留置导管的存在情况和伴随用药进行调整后,仅使用β受体阻滞剂(BBL)、钙通道阻滞剂(CCB)以及血管紧张素转换酶抑制剂(ACEI)和血管紧张素受体阻滞剂(ARB)仍与生存显著相关(BBL优势比[OR]0.32[95%置信区间(CI)0.17至0.61];CCB OR 0.42[95%CI 0.23至0.76];ACEI/ARB OR 0.51[95%CI 0.28至0.95])。ACEI/ARB和BBL对生存的有益作用随着药物剂量的增加而依次增强。事件发生时使用BBL是24小时生存的唯一预测变量。因此,在这个血液透析队列中,传统心血管危险因素与心脏骤停后的生存无关。与BBL、CCB和ACEI/ARB相关的益处表明,这些药物可能会提高心脏骤停后的生存几率。